Elevated Serum Bioactive Prolactin Concentrations in Patients with Systemic Lupus Erythematosus Are Associated with Disease Activity as Disclosed by Homologous Receptor Bioassays

Journal of Rheumatology

Volumn 34, Issue 7, 2007, Pages 1514-1521

  Cárdenas Mondragón, Guadalupe ^a   Ulloa Aguirre, Alfredo ^a   Isordia Salas, Irma ^c   Goffin, Vincent ^b   Leaños Miranda, Alfredo ^a  

^a Hospital Luis Castelazo Ayala   (Mexico)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Disease activity; Macroprolactin; Prolactin; Prolactin bioassays; Systemic lupus erythematosus

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; LEUKEMIA INHIBITORY FACTOR; PREDNISONE; PROLACTIN; THROMBOPOIETIN;

ADULT; ARTICLE; DISEASE ACTIVITY; FEMALE; HUMAN; HYPERPROLACTINEMIA; IMMUNOREACTIVITY; IN VITRO STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RECEPTOR BINDING; SERODIAGNOSIS; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANIMALS; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HEALTH STATUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; PROLACTIN; RATS; RECEPTORS, PROLACTIN; SEVERITY OF ILLNESS INDEX;

EID: 34447520265     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19:225-68.
2. Kelly PA, Djiane J, Postel-Vinay MC, Edery M. The prolactin/growth hormone receptor family. Endocr Rev 1991;12:235-51.
3. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934-8.
4. Lavalle C, Loyo E, Paniagua R, et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol 1987;14:268-72.
5. Blanco-Favela F, Quintal-Alvarez G, Leaños-Miranda A. Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol 1999;26:55-9.
6. Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 2001;10:554-61.
7. Pacilio M, Migliaresi S, Meli R, Ambrosone L, Bigliardo B, Di Carlo R. Elevated bioactive prolactin levels in systemic lupus erythematosus-association with disease activity. J Rheumatol 2001;28:2216-21.
8. Leanos-Miranda A, Pascoe-Lira D, Chávez-Rueda KA, Blanco-Favela F. Anti-prolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity. J Rheumatol 2001;28:1546-53.
9. McMurray R, Keisler D, Kanuekel K, Izui S, Walker SE. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 1991;147:3780-7.
10. McMurray R, Keisler D, Kondo K, Walker S. Hyperprolactinemia in male NZB/NZW (B/W) F1 mice: accelerated autoimmune disease with normal circulating testosterone. Clin Immunol Immunopathol 1994;71:338-43.
11. Peeva E, Grimaldi C, Spatz L, Diamond B. Bromocriptine restores tolerance in estrogen-treated mice. J Clin Invest 2000;106:1373-9.
12. Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 1995;16:354-64.
13. Leanos A, Pascoe D, Fraga A, Blanco-Favela F. Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus 1998;7:398-403.
14. Leanos-Miranda A, Chávez-Rueda KA, Blanco-Favela F. Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:866-75.
15. Leanos-Miranda A, Pascoe-Lira D, Chávez Rueda KA, Blanco-Favela F. Peristence of macroprolactinemia due to antiprolactin autoantibody, before, during, and after pregnancy in a woman with systemic lupus erythematosus. J Clin Endocrinol Metab 2001;86:2619-24.
16. Cruz J, Aviña-Zuvieta A, Martínez de la Escalera G, Clapp C, Lavalle C. Molecular heterogeneity of prolactin in the plasma of patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:1331-5.
17. García M, Colombani-Vidal ME, Zylbersztein CC, et al. Analyses of molecular heterogeneity of prolactin in human systemic lupus erythematosus. Lupus 2004;13:575-83.
18. Hattori N. The frequency of macroprolactinemia in pregnant women and heterogeneity of its etiologies. J Clin Endocrinol Metab 1996;81:586-90.
19. Pascoe-Lira D, Duran-Reyes G, Contreras-Hernández I, Manuel-Apolinar L, Blanco-Favela F, Leaños-Miranda A. Frequency of macroprolactinemia due to autoantibodies against prolactin in pregnant women. J Clin Endocrinol Metab 2001;86:924-9.
20. De Schepper J, Schiettecatte J, Velkeniers B, et al. Clinical and biological characterization of macroprolactinemia with and without prolactin-IgG complexes. Eur J Endocrinol 2003;149:201-7.
21. Jackson RD, Malarkey WB. Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. J Clin Endocrinol Metab 1985;61:258-64.
22. Leite V, Cosby H, Sobrinho LG, Fresnoza A, Santos MA, Friesen HG. Characterization of big big prolactin in patients with hyperprolactinemia. Clin Endocrinol 1992;37:365-72.
23. Leanos-Miranda A, Cárdenas-Mondragón G. Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. Rheumatology Oxford 2006;45:97-101.
24. Bernichtein S, Jeay S, Vaudry R, Kelly PA, Goffin V. New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity. Endocrine 2003;20:177-90.
25. Leanos-Miranda A, Cárdenas-Mondragón G, Rivera-Leaños R, Ulloa-Aguirre A, Goffin V. Application of new homologous in vitro bioassays for human lactogens to assess the actual bioactivity of human prolactin isoforms in hyperprolactinemic patients. Clin Endocrinol 2006;65:146-53.
26. Glezer A, Soares CR, Vieira JG, et al. Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay. J Clin Endocrinol Metab 2006;91:1048-55.
27. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
28. Bombardier C, Gladman D, Urowitz M, Caron D, Chang CH. The Committee on Prognosis Studies in SLE: Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
29. Leanos-Miranda A, Pascoe-Lira D, Chávez-Rueda KA, Blanco-Favela F. Detection of macroprolactinemia with the polyethylene glycol precipitation test in systemic lupus erythematosus patients with hyperprolactinemia. Lupus 2001;10:340-5.
30. Leanos-Miranda A, Contreras-Hernández I. Antiprolactin autoantibodies are associated with hyperprolactinemia status in men infected with human immunodeficiency virus. Endocrine 2002;19:139-46.
31. Wakao H, Gouilleux F, Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J 1994;13:2182-91.
32. Mok CC, Lau CS, Tan CF. Prolactin profile in a cohort of Chinese systemic lupus erythematosus patients. Br J Rheumatol 1997;36:986-9.
33. McMurray RW, Weidensaul D, Allen S, Walker S. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 1995;22:2084-91.
34. Alvarez-Nemegyei J, Covarrubias-Cobos A, Escalante-Triay F, Soza-Munoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 1998;7:414-9.
35. Farkouh NH, Packer MG, Frantz AG. Large molecular size prolactin with reduced receptor activity in human serum: high proportion in basal state and reduction after thyrotropin-releasing hormone. J Clin Endocrinol Metab 1979;47:1026-32.
36. Fraser IS, Lun ZG, Zhou JP, et al. Detailed assessment of big-big prolactin in women with hyperprolactinemia and normal ovarian function. J Clin Endocrinol Metab 1989;69:585-92.